Back to Clinical Trials
N/ARecruiting

Spatial-Motor Stroke-Rehab Study

Sponsored by Emory University

About this study

The purpose of this study is to understand how prism adaptation training with and without electrical stimulation changes visuospatial behavior, motor system neurophysiology, and walking dysfunction.

Spatial Neglect (SN) is defined as pathological asymmetric spatial behavior causing functional disability and occurs in greater than 50% of individuals with right hemisphere stroke. SN post-stroke is associated with increased fall risk, increased hospital length of stay, poorer rehabilitation outcomes, and severe long-term disability. Prism adaptation therapy (PAT) is an evidence-based treatment for SN after stroke, however, the effects of SN on gait are not well known. Neuromuscular electrical stimulation delivered via surface electrodes is a common therapeutic adjunct in stroke rehabilitation, including for SN and gait training. However, the additive therapeutic effects of combining electrical stimulation and PAT, as well as the effects of motor training on gait deficits associated with …

Where this study is enrolling (3)

Who can participate

Inclusion criteria

  • ✓Young Adults Able Bodied (YAB) Individuals
  • ✓18-30 years
  • ✓Able-Bodied (healthy without any physical disability or neurological disorder)
  • ✓Older Adults Able-Bodied Individuals (OAB)
  • ✓45-90 years
  • ✓Able-Bodied (healthy without any physical disability or neurological disorder)
  • ✓Individuals with right hemisphere stroke (40-90 years)
  • ✓\>3 months following stroke.
  • ✓Presence of Aiming SN
  • ✓Ability to walk \>10m with or without assistive devices.
  • ✓Unilateral left-sided hemiparesis with gross arm strength of ≤ grade 4/5 on the Medical Research Council Scale
  • ✓Ability to follow 3-stage commands and provide informed consent.

Exclusion criteria

  • ✕Young Adults Able-Bodied (YAB) Individuals and Older Adults Able-Bodied Individuals (OAB)
  • ✕History or evidence of orthopedic or physical disability
  • ✕History or evidence of neurological pathology
  • ✕Pregnancy (female)
  • ✕Uncontrolled hypertension
  • ✕Cardiac pacemaker or other implanted electronic system
  • ✕Presence of skin conditions preventing the electrical stimulation setup
  • ✕Impaired sensation in the left upper limb.
  • ✕Bruises or cuts at the stimulation electrode placement site
  • ✕Concurrent enrollment in rehabilitation or another investigational study.
  • ✕History or evidence of orthopedic or physical disability interfering with study procedures
  • ✕History or evidence of neurological pathology or disorder
  • ✕Severe uncontrolled medical problems (e.g., hypertension, cardiovascular disease, rheumatoid arthritis, active cancer or renal disease, epilepsy) that may interfere with study procedures
  • ✕Contraindications to TMS, such as metal implants, medications that can increase cortical excitability, and unexplained dizziness in the past 6 months
  • ✕Individuals with right hemisphere stroke (40-90 years)
  • ✕History or brainstem strokes
  • ✕Cerebellar disorders
  • ✕Impaired sensation in the left upper limb.
  • ✕History of other neurological disorders
  • ✕Uncontrolled hypertension
  • ✕Cardiac pacemaker or other implanted electronic system
  • ✕Pregnancy (female)
  • ✕Presence of skin condition
  • ✕Bruises at the electrode placement site
  • ✕Severe uncontrolled medical problems (e.g., hypertension, cardiovascular disease, rheumatoid arthritis, active cancer or renal disease, epilepsy) or other medical conditions that can interfere with study procedures
  • ✕Contraindications to TMS, such as metal implants in the brain, medications that will increase cortical excitability, etc.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.